Vesper Medical is a medical device company dedicated to the development of a novel venous stent for the treatment of a variety of venous diseases. The company had achieved CE Mark and has initiated the VIVID trial in the US for FDA approval. Vesper was founded in 2016 as a spin-out of Intact Vascular.

In 2022, Royal Philips acquired 100% of the Vesper shares, providing Gilde with an attractive return within a three-year holding period.